Skip to main content
SpringerLink
Log in

Once-Daily Memantine

A Guide to its Use in Moderate to Severe Alzheimer’s Disease in the EU

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

In the EU, once-daily memantine 20 mg (Axura®, Ebixa®) is an option for the management of patients with moderate to severe Alzheimer’s disease (AD). In pooled clinical trials and studies in the clinical practice setting, memantine 20 mg/day improved cognition, functional ability and behavioural symptoms in this patient population. The beneficial effects of memantine are associated with delays in the need for full-time care, which were predicted to result in cost savings relative to standard care in recent cost-utility analyses in patients with moderate to severe AD conducted in EU countries. Memantine is well tolerated, with an adverse event profile that is similar to that with placebo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59:1737–46.

    Article  PubMed  Google Scholar 

  2. Atri A. Effective pharmacological management of Alzheimer’s disease. Am J Manag Care. 2011;17(Suppl 13):S346–55.

    PubMed  Google Scholar 

  3. Burns A, Iliffe S. Alzheimer’s disease. BMJ. 2009;338:467–71.

    Google Scholar 

  4. Committee for Medicinal Products for Human Use. Guideline on medicinal products for the treatment of Alzheimer’s disease and other dementias. London: Eur. Med. Agency; 2008.

    Google Scholar 

  5. Stefanacci RG. The costs of Alzheimer’s disease and the value of effective therapies. Am J Manag Care. 2011;17(Suppl 13):S356–62.

    PubMed  Google Scholar 

  6. Cappell J, Herrmann N, Cornish S, et al. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer’s disease. CNS Drugs. 2010;24(11):909–27.

    Article  PubMed  Google Scholar 

  7. Levy K, Lanctôt KL, Farber SB, et al. Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease relieve caregiver burden? Drugs Aging. 2012;29(3):167–79.

    Article  PubMed  CAS  Google Scholar 

  8. Patel L, Grossberg GT. Combination therapy for Alzheimer’s disease. Drugs Aging. 2011;28(7):539–46.

    Article  PubMed  CAS  Google Scholar 

  9. Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol. 2008;6(1):55–78.

    Article  PubMed  CAS  Google Scholar 

  10. Herrmann N, Chau SA, Kircanski I, et al. Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs. 2011;71(15):2031–65.

    Article  PubMed  CAS  Google Scholar 

  11. Axura (memantine hydrochloride): summary of prescribing information. London: European Medicines Agency; 2012 Jun 12.

  12. Ebixa (memantine hydrochloride): summary of prescribing information. London: European Medicines Agency; 2012 Jun 12.

  13. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–41.

    Article  PubMed  CAS  Google Scholar 

  14. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.

    Article  PubMed  CAS  Google Scholar 

  15. van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136–43.

    Article  PubMed  Google Scholar 

  16. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24(1):20–7.

    Article  PubMed  CAS  Google Scholar 

  17. Winblad B, Gauthier S, Aström D, et al. Memantine benefits functional abilities in moderate to severe Alzheimer’s disease. J Nutr Health Aging. 2010;14(9):770–4.

    Article  PubMed  CAS  Google Scholar 

  18. Mecocci P, Bladström A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009;24(5):532–8.

    Article  PubMed  Google Scholar 

  19. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537–45.

    Article  PubMed  CAS  Google Scholar 

  20. Ferris S, Ihl R, Robert P, Winblad B, et al. Treatment effects of memantine on language in moderate to severe Alzheimer’s disease patients. Alzheimers Dement. 2009;5(5):369–74.

    Article  PubMed  CAS  Google Scholar 

  21. Hellweg R, Wirth Y, Janetzky W, et al. Efficacy of memantine in delaying clinical worsening in Alzheimer’s disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. Int J Geriatr Psychiatry. 2012;27(6):651–6.

    Article  PubMed  Google Scholar 

  22. Calabrese P, Essner U, Forstl H. Memantine (Ebixa) in clinical practice: results of an observational study. Dement Geriatr Cogn Disord. 2007;24(2):111–7.

    Article  PubMed  CAS  Google Scholar 

  23. Clerici F, Vanacore N, Elia A, et al. Memantine in moderately-severe-to-severe Alzheimer’s disease: a postmarketing surveillance study. Drugs Aging. 2009;26(4):321–32.

    Article  PubMed  CAS  Google Scholar 

  24. Clerici F, Vanacore N, Elia A, et al. Memantine effects on behaviour in moderately severe to severe Alzheimer’s disease: a post-marketing surveillance study. Neurol Sci. 2012;33(1):23–31.

    Article  PubMed  Google Scholar 

  25. Rainer M, Wuschitz A, Jagsch C, et al. Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study. J Neural Transm. 2011;118(8):1255–9.

    Article  PubMed  CAS  Google Scholar 

  26. Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French National Health Care database. Neuroepidemiology. 2008;31(3):193–200.

    Article  PubMed  Google Scholar 

  27. Jones RW, Bayer A, Inglis F, et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22(3):258–62.

    Article  PubMed  Google Scholar 

  28. Reisberg B, Doody R, Stoffler A, et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006;63(1):49–54.

    Article  PubMed  Google Scholar 

  29. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704–15.

    Article  PubMed  Google Scholar 

  30. Porsteinsson AP, Grossberg GT, Mintzer J, et al. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–9.

    Article  PubMed  CAS  Google Scholar 

  31. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13(1):97–107.

    PubMed  CAS  Google Scholar 

  32. Homma A. Efficacy of memantine in patients with moderately severe to severe Alzheimer’s disease in Japan (dose-finding study) [poster]. 11th Congress of the European Federation of Neurological Societies, Brussels; 2008 Aug 25–28.

  33. Forest Laboratories Clinical Trial Registry. Study MEM-MD-22: a randomized, double-blind, placebo-controlled evaluation of the effectiveness and safety of memantine in nursing home residents with moderate to severe Alzheimer’s disease. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-22_final.pdf. Accessed 2012 Aug 23.

  34. Lundbeck Clinical Trial Registry. Study 10116: a randomized, double-blind, placebo-controlled evaluation of the effectiveness and safety of memantine in patients with dementia of the Alzheimer’s type. http://www.lundbecktrials.com/Data/PDFs/10116_Final_11Oct2006_CTRS.pdf. Accessed 2012 Aug 23.

  35. Pouryamout L, Dams J, Wasem J, et al. Economic evaluation of treatment options in patients with Alzheimer’s disease: a systematic review of cost-effectiveness analyses. Drugs. 2012;72(6):789–802.

    Article  PubMed  Google Scholar 

  36. Rive B, Grishchenko M, Guilhaume-Goulant C, et al. Cost effectiveness of memantine in Alzheimer’s disease in the UK. J Med Econ. 2010;13(2):371–80.

    Article  PubMed  CAS  Google Scholar 

  37. Hoogveldt B, Rive B, Severens J, et al. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands. Neuropsychiatr Dis Treat. 2011;7:313–7.

    PubMed  CAS  Google Scholar 

  38. Rive B, Aarsland D, Grishchenko M, et al. Cost-effectiveness of memantine in moderate and severe Alzheimer’s disease in Norway. Int J Geriatr Psychiatry. 2012;27(6):573–82.

    Article  PubMed  CAS  Google Scholar 

  39. McKeage K. Memantine: a review of its use in moderate to severe Alzheimer’s disease. CNS Drugs. 2009;23(10):881–97.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

This article was updated from CNS Drugs 2009; 23 (10): 881-97 [39]. The preparation of this article and the article from which it was adapted were not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson & Kate McKeage

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Additional information

The manuscript was reviewed by Emina Obarcanin, Sarajevo, Bosnia and Herzegovina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A., McKeage, K. Once-Daily Memantine. Drugs Aging 30, 51–58 (2013). https://doi.org/10.1007/s40266-012-0041-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-012-0041-0

Keywords

Search

Navigation